Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Not yet recruiting × HER2-positive Breast Cancer × dalpiciclib × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 5 HR+/HER2- Advanced Breast Cancer 2 Squamous Cell Carcinoma of Head and Neck 1 Ovarian Neoplasms 1 HER2-positive Breast Cancer 1 Advanced Breast Cancer 1

Interventions

pyrotinib 5 Trastuzumab 5 pertuzumab 2 tucatinib 1 neratinib 1 exemestane 1 dalpiciclib 1 Paclitaxel 1 Leuprolide 1 Goserelin 1 Fulvestrant 1 Docetaxel 1 Capecitabine 1 Anastrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07179939 2025-09-18

Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study

Fudan University

Phase 2 Not yet recruiting

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡